Leishmaniasis (Kala-Azar) Global Clinical Trials Review, H2, 2016

GlobalData
118 Pages - GLDATA57872
$2,500.00

Summary

GlobalData's clinical trial report, “Leishmaniasis (Kala-Azar) Global Clinical Trials Review, H2, 2016" provides an overview of Leishmaniasis (Kala-Azar) clinical trials scenario. This report provides top line data relating to the clinical trials on Leishmaniasis (Kala-Azar). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies Mentioned

International Centre for Diarrhoeal Disease Research Bangladesh
Medecins Sans Frontieres
Knight Therapeutics Inc
Lifecare Innovations Pvt Ltd
Aeterna Zentaris Inc
Zydus Cadila Healthcare Ltd
GVK Biosciences Pvt Ltd
Fast-Track Drugs & Biologics LLC
Dafra Pharma International Ltd
Bharat Serums And Vaccines Ltd

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Leishmaniasis (Kala-Azar) to Infectious Disease Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Leishmaniasis (Kala-Azar) to Infectious Disease Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials 27
Prominent Drugs 29
Latest Clinical Trials News on Leishmaniasis (Kala-Azar) 30
Nov 03, 2016: Newly discovered protein may hold key to better drugs for neglected diseases 30
Clinical Trial Profile Snapshots 31
Appendix 115
Abbreviations 115
Definitions 115
Research Methodology 116
Secondary Research 116
About GlobalData 117
Contact Us 117
Disclaimer 117
Source 118

List of Tables
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials by Region, 2016* 6
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Europe, Top Countries, 2016* 10
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
Proportion of Leishmaniasis (Kala-Azar) to Infectious Disease Clinical Trials, G7 Countries (%), 2016* 14
Leishmaniasis (Kala-Azar) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Leishmaniasis (Kala-Azar) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Leishmaniasis (Kala-Azar) to Infectious Disease Clinical Trials, E7 Countries (%), 2016* 17
Leishmaniasis (Kala-Azar) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Leishmaniasis (Kala-Azar) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Leishmaniasis (Kala-Azar) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Europe, Top Countries (%), 2016* 10
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
Proportion of Leishmaniasis (Kala-Azar) to Infectious Disease Clinical Trials, G7 Countries (%), 2016* 14
Leishmaniasis (Kala-Azar) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Leishmaniasis (Kala-Azar) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Leishmaniasis (Kala-Azar) to Infectious Disease Clinical Trials, E7 Countries (%), 2016* 17
Leishmaniasis (Kala-Azar) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Leishmaniasis (Kala-Azar) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Leishmaniasis (Kala-Azar) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Leishmaniasis (Kala-Azar) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Leishmaniasis (Kala-Azar) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 116

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports